Nanotechnologies for cancer: developing new polymer-drug conjugates for the treatment of a range of cancers at University of Reading on FindAPhD.com

Dr F Greco, Prof H Osborn Applications accepted all year round Self-Funded PhD Students Only

Add
to
shortlist

Remove
from
shortlist

Reading United Kingdom Cancer Biology Cell Biology Pharmaceutical Chemistry Polymer Chemistry Synthetic Chemistry

About the Project

Polymer anticancer-drug conjugates are drug delivery systems in which a low molecular weight anticancer agent is covalently conjugated to a water-soluble polymeric carrier. Their main advantages compared to the parent free drug are: (i) passive accumulation in the tumour tissue by means of the well-described enhanced permeability and retention (EPR) effect, (ii) decreased toxicity, (iii) increased solubility (anticancer drugs are usually poorly water-soluble), (iv) bypassing of certain mechanisms of drug resistance such as P-glycoprotein mediated resistance. Following accumulation in the tumour tissue, polymer-drug conjugates are internalised into tumour cells by endocytosis and trafficked to the lysosomal compartment. In the lysosomes, the linker is cleaved in response to environmental stimuli (usually low pH or peptidases such as cathepsin B) and the drug is released.

This programme aims to develop new polymer-drug conjugates for the treatment of a range of cancers. In particular, the incorporation of drug-polymer linkers that are sensitive to enzymes within a range of tumours will be probed to potentially prepare prodrugs for cancer. These polymeric prodrugs should be inactive until they reach the enzyme required for drug release, and since the enzymes will be specific to tumours, selective delivery should result. This approach will present an important advantage compared to traditional polymer anticancer drug conjugates. Whilst the selectivity of the latter relies only on the EPR effect, the proposed system will display a double targeting mechanism: the EPR effect followed by specific activation in the tumour tissue.

The project is highly interdisciplinary and involves a collaboration between Med Chem (Prof Osborn) and Pharmaceutics (Greco)

Funding Notes

Applicants should hold, or expect to shortly gain, a 2(i) or better degree in a related discipline

How good is research at University of Reading in Allied Health Professions, Dentistry, Nursing and Pharmacy?

Research output data provided by the Research Excellence Framework (REF)

Click here to see the results for all UK universities

Email Now

Recipient *

Your first name *

Your last name *

Your telephone number

Your email address *

Where are you currently living? *

Your nationality *

Insert previous message

Your message * (please edit as appropriate)

You haven’t included a message. Providing a specific message means universities will take your enquiry more seriously and helps them provide the information you need.
Why not add a message here

* required field

The information you submit to University of Reading will only be used by them or their data partners to deal with your enquiry, according to their privacy notice. For more information on how we use and store your data, please read our privacy statement.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Your enquiry has been emailed successfully

You can view your previously sent enquiries in MyFindAPhD

We’ve won a FindAMasters and FindAPhD Postgrad Award!

As a previous winner of a Postgrad Award, our university community has been recognised for their excellence in, and dedication to, postgraduate education. Studying with us means you’ll be part of a supportive environment that has been celebrated for its achievements and positive impact on our postgraduate students.

Find out more